Everand Logo

Welcome to Everand!

  • STAT

    Before a biotech stock debacle, one Republican congressman made a prescient trade

    Rep. John Culberson made a prescient sale to avoid losses when a tiny biotech's stock tanked. The stock was a favorite of several GOP representatives.
    by Damian Garde Jul 03, 2017 2 minutes
    Rep. John Culberson made a prescient sale to avoid losses when a tiny biotech company's stock tanked.

    A biotech stock meltdown last week led to huge paper losses for several congressional Republicans who had bought into the tiny company. But one politician-turned-investor was spared. Turns out, he had sold his shares just two weeks before news of a negative clinical trial decimated the company’s value.

    Rep. John Culberson of Houston was among a half dozen House Republicans to invest in Innate Immunotherapeutics,

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
    Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT2 min readAmerican Government
    STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
    The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

    Related Books & Audiobooks